Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Suterra LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 active matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of the portfolio under 1 examiner suggests a highly focused prosecution path for the company at this stage.
The busiest examiner for the portfolio is BOWLES, DAVID PAUL, who is responsible for 1 pending office action. This figure represents the company's current pending workload. Because the portfolio is distributed across 1 distinct art unit, the examiner's specific internal policies and historical trends will likely dictate the immediate outcomes for the pending application.
Practitioners should note that with 1 distinct examiner handling the pending matter, the prosecution strategy is dependent on the interactions with BOWLES, DAVID PAUL. The alignment of the Biotechnology & Pharmaceuticals technology area with the current filings indicates that the intellectual property focus is concentrated. Future filings may expand these metrics, but the current data shows a centralized point of contact within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552621 | LIPOSOME FORMULATIONS FOR PESTICIDE DELIVERY AND METHODS FOR PRODUCING AND USING THE SAME | BOWLES, DAVID PAUL | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18552621 | LIPOSOME FORMULATIONS FOR PESTICIDE DELIVERY AND METHODS FOR PRODUCING AND USING THE SAME | BOWLES, DAVID PAUL | 1654 | §103§112DP | Non-Final OA | — | Pending | Sep 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuterra LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David Paul Bowles has the most, with 1 of Suterra LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
